In conclusion, our in vitro studies show that RTX-IgG2, in combination with tumor-targeting mAbs, enhances ADCP of CD20+ B-cell lymphoma cells via CD20-mediated apoptosis and CD47 reduction. Here, CD47 is linked to neoplasm.